Disease · MONDO_0006993

systolic heart failure

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. systolic heart failure. Diseases, record MONDO_0006993. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0006993

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: systolic heart failure; Open Targets
Open Targets ID: MONDO_0006993; Open Targets
Other names: Heart Failure, Systolic; Open Targets
Disease Ontology: DOID:9651; Disease Ontology
MeSH: D054143; MeSH
Highest stage of its drugs: Approval, for 1 of its 9 drugs, from EMA Human Drugs; Open Targets

Drugs9

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
DAPAGLIFLOZIN	CHEMBL429910	Small molecule	Approval	EMA Human Drugs	3	0	0	Drugs and targets
HUMAN NEUREGULIN-1 RECOMBINANT (177-237)	CHEMBL4594600		Phase 3	ClinicalTrials.gov	1	1	0	Drugs and targets
UDENAFIL	CHEMBL2103849	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
ALISKIREN	CHEMBL1639	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
ANAKINRA	CHEMBL1201570	Protein	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
RAMIPRIL	CHEMBL1168	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
NESIRITIDE	CHEMBL1201668	Protein	Phase 1/2	ClinicalTrials.gov	1	1	1	Drugs and targets
NELUTROCTIV	CHEMBL5314433	Small molecule	Unknown	USAN	1	0	0	Drugs and targets
OMECAMTIV MECARBIL	CHEMBL1800955	Small molecule	Unknown	EMA Human Drugs	1	0	0	Drugs and targets

Targets13

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
ACE	Angiotensin-converting enzyme	1	Angiotensin-converting enzyme inhibitor	Phase 2	https://conductscience.org/library/genes/1636	Drugs and targets
IL1R1	Interleukin-1 receptor type 1	1	Interleukin-1 receptor antagonist	Phase 2	https://conductscience.org/library/genes/3554	Drugs and targets
MYH6	Cardiac myosin	1	Cardiac myosin activator	Unknown	https://conductscience.org/library/genes/4624	Drugs and targets
MYH7	Cardiac myosin	1	Cardiac myosin activator	Unknown	https://conductscience.org/library/genes/4625	Drugs and targets
MYH7B	Cardiac myosin	1	Cardiac myosin activator	Unknown	https://conductscience.org/library/genes/57644	Drugs and targets
MYL2	Cardiac myosin	1	Cardiac myosin activator	Unknown	https://conductscience.org/library/genes/4633	Drugs and targets
MYL3	Cardiac myosin	1	Cardiac myosin activator	Unknown	https://conductscience.org/library/genes/4634	Drugs and targets
MYL4	Cardiac myosin	1	Cardiac myosin activator	Unknown	https://conductscience.org/library/genes/4635	Drugs and targets
MYL7	Cardiac myosin	1	Cardiac myosin activator	Unknown	https://conductscience.org/library/genes/58498	Drugs and targets
NPR1	Atrial natriuretic peptide receptor 1	1	Atrial natriuretic peptide receptor A agonist	Phase 1/2	https://conductscience.org/library/genes/4881	Drugs and targets

1 to 10 of 13

See all 13 targets

Trials4

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00923156	Effects of Aliskiren, Ramipril, and the Combination on Levels of Angiotensin II in Patients With Decompensated Systolic Heart Failure	Phase 2	123	2012-03-05	Heart Failure	ALISKIREN, RAMIPRIL	Its record names the disease	ClinicalTrials.gov
NCT03797001	Interleukin-1 Blockade In Recently Decompensated Heart Failure - 2	Phase 2	102	2025-08-06	Heart Failure, Systolic, Inflammation	ANAKINRA	Its record names the disease	ClinicalTrials.gov
NCT00387621	Natriuretic Peptide System as Therapy in Human Preclinical Left Ventricle Dysfunction	Phase 1/2	58	2012-05-17	Congestive Heart Failure	NESIRITIDE	Its record names the disease	ClinicalTrials.gov
NCT01646515	Udenafil Therapy to Improve Symptomatology, Exercise Tolerance and Hemodynamics in Patients With Chronic Systolic Heart Failure	Phase 3	41		Systolic Heart Failure	UDENAFIL	Its record names the disease	ClinicalTrials.gov

Comparisons in its trials3

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Nesiritide vs Placebo: serious adverse events	1 of 58	0 of 58	116	NCT00387621	Trial comparisons
Anakinra vs Placebo: deaths from any cause	0 of 68	1 of 34	102	NCT03797001	Trial comparisons
Anakinra vs Placebo: serious adverse events	12 of 68	6 of 34	102	NCT03797001	Trial comparisons

Papers from its trials7

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
42751917	DERIVED	1	PubMed
42455969	DERIVED	1	PubMed
41431894	DERIVED	1	PubMed
35706006	DERIVED	1	PubMed
35283262	DERIVED	1	PubMed
33089502	DERIVED	1	PubMed
23799908	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0006993

GET https://conductscience.org/api/diseases/v1/MONDO_0006993/drugs

API reference For AI assistants